6 edition of Trends in Pharmacological Research on Platelet Activating Factor (Paf in Japan) found in the catalog.
August 1988 by Medico Dental Media International .
Written in English
|Contributions||Kensuke Kisara (Editor)|
|The Physical Object|
|Number of Pages||208|
Platelet-activating factor (PAF) is a lipid mediator with important pro-inflammatory effects, being synthesized by several cell types including kidney cells. Although there is .
Plays of Eugene ONeill (Vol. 1)
Sculptura-historico-technica, or, The history and art of ingraving ...
Crises in modern thought
Endocrinology (The New Medicine)
twentieth-century newspaper press in Britain
Pathology and physiology of burns, 1942-1951
Fodo rs the Netherlands, Belgium, Luxembourg
Recreation in the East Midlands
The oeconomy of human life
Deinstitutionalization and mental health services.
Trends in pharmacological research on platelet activating factor (PAF) in Japan. Tokyo ; St. Louis: Ishiyaku EuroAmerica, © (OCoLC) Online version: Symposium on Problems on PAF (11th: Tohoku College of Pharmacy). Trends in pharmacological research on platelet activating factor (PAF) in Japan. Platelet-activating factor, also known as PAF, PAF-acether or AGEPC (acetyl-glyceryl-ether-phosphorylcholine), is a potent phospholipid activator and mediator of many leukocyte functions, platelet aggregation and degranulation, inflammation, and is also involved in changes to vascular permeability, the oxidative burst, chemotaxis of leukocytes, as well as CAS Number: Platelet-activating factor (PAF) is a phospholipid that was discovered as a platelet-agglutinating factor derived from rabbit basophils and as a depressor substance derived from the renal medulla.
To generate PAF, phospholipase A 2 removes fatty acid in the sn-2 position of the ester-type membrane phospholipid, followed by acetylation. Platelet-activating factor today B. Vargaftig* and J. Benvenistet * Unitd des Venms, D~partement de Physiopathologie Exl~rimentale, institut Pasteur, 28 rue du Dr.
Rout. Paris Ce France and t lNSERM UUniversit~ Paris-Sud, Clamart, France, It is now clearly established that the release of ADP and the formation of Cited by: Trends in Pharmacological Research on Platelet Activating Factor (Paf in Japan) by Yasumi Ogura (Editor), Kensuke Kisara (Editor) Hardcover, Pages, Published ISBN / ISBN / Need it Fast.
2 day shipping optionsPages: Author information: (1)Mario Negri Institute for Pharmacological Research, Bergamo, Italy. To determine whether platelet-activating factor (PAF) has a physiological role in the process of primary hemostasis in the rabbit, we measured skin bleeding times in animals given orally a specific PAF-receptor antagonist L,Cited by: Platelet aggregation is mediated by platelet activating factor, which also causes bronchoconstriction, similar to migraine [21, 22].
Substance P is involved in migraine pathogenesis and is also. Platelet-activating factor (PAF) is a phospholipid mediator that regulates the functions of a variety of cells in the peripheral tissues and in the nervous system. Overview: Platelet-activating factor (PAF, 1-O-alkylacetyl-sn-glycerophosphocholine) is a biologically active phospholipid acts by binding to a unique G protein-coupled seven transmembrane receptor (PAF-R) and activates multiple intracellular signalling pathways by coupling to the G q/11 and G i/o families of G proteins.
PAF-R is activated by PAF and its. In an earlier issue of Trends in Pharmacologocal Sciences, Vargaftig and Benveniste 1 reviewed the biological properties of platelet activating factor (Paf-acether).
They emphasized the effect of Paf-acether upon platelets, but also alluded to a role for this material in asthma and inflammation. The usefulness of the human hair follicle as a biopsy tissue for determining genotypes in inborn errors of metabolism is due to tow major facts: firts, the human hair follicle can easily be removed from the donor without any harm or risk; second, due to the fact that most hair follicles are of monoclonal origin they are highly suitable for determining X-linked diseases.
The purpose of the study was to explore the association between plasma platelet activating factor (PAF) and platelet activating factor acetylhydrolase (PAF-AH) levels and risk of coronary heart disease (CHD) or blood stasis syndrome (BSS) of CHD. Questionnaire, routine clinical assays and plasma levels of PAF, PAF-AH and inflammatory factors hs-CRP and IL-6 Cited by: Abstract.
Platelet activating factor (PAF) is a low molecular weight, ether-linked phospholipid originally identified as a soluble factor, released from sensitized rabbit basophils during IgE anaphylaxis, that was capable of aggregating rabbit platelets [1, 2].Author: Gordon Dent.
In this minireview, we refer to recent results as far as the Platelet Activating Factor (PAF) inhibitors are concerned. At first, results of organic compounds (natural and synthetic ones and specific and nonspecific) as inhibitors of PAF are reported.
Emphasis is given on recent results about a new class of the so-called metal-based inhibitors of by: Synthesis of PAF. Physiological and Pathophysiological effects of PAF. Platelet aggregation. Thrombus formation.
Recent research. Pharmacological actions of PAF. PAF antagonists. 2 3. What is platelet activating factor.?. Platelet-activating factor is a potent biological mediator that exerts its effects in a variety of cells and tissues. Antigenic challenge of IgE-sensitised basophils releases a platelet-activating, factor (PAF), probably a 1-lysophosphatidylcholine5.
PAF has a potent. Abstract: Platelets are involved in haemostasis and vessel integrity under physiologic conditions, and in thrombosis under disease states.
Platelet activation upon stimulation with various agonists in vitro and in vivo, is strongly dependent on an increase of intracellular Ca 2+ concentration. The latter results from Ca 2+ release by the dense tubular system (DTS), and Ca 2+ entry from the. Current Trends in Platelet-Activating Factor Research The latest published research in relation to PAF is vast and traverses a plethora of biological systems and pathways.
The following sections provide a brief overview of some of the most exciting PAF by: 1. Introduction. The single Platelet-activating Factor receptor (PAFR) is a G-protein coupled receptor present in the plasma and nuclear membranes of the majority of cells of the vascular and innate immune system that activates a variety of pathways involved in inflammation, oncogenic transformation, tumor growth, angiogenesis and metastasis.
Chang et al., "Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects," Proceedings of the National Academy of.
Coagulation factors, phosphatidylserine, platelet receptors, thrombin Summary Platelet activation and blood coagulation are complementary, mutually dependent processes in haemostasis and thrombosis.
Platelets interact with several coagulation factors, while the coagulation product thrombin is a potent platelet-activating agonist. documented that ginkgo extract is a potent inhibitor of platelet activating factor. Kleinjnen and Knipschild agreed with these findings and postulated that subdural hematomas were directly due to the presence of abnormal platelet aggregation as a result of the ingestion of ginko..
Since platelet-activating factor (PAF) plays a role in primary hemostasis, we studied platelet aggregation in response to PAF in 40 patients with chronic uremia on regular hemodialysis and 12 control subjects.
Our results showed that in 28 of 40 uremics, platelet aggregation response to PAF was normal. Copyright ©American Society for Neurochemistry. Published by Elsevier Inc. All rights reserved. References Baek, R. C, Martin, D. R., Cox, N. R., & Seyfried. Factor A financial institution that buys a firm's accounts receivable and collects the accounts.
Factor A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount.
The factor then assumes the credit risk associated. Recently, a number of studies have examined the association between aspirin resistance and several receptors on the surface of platelets, [sup] such as genetic polymorphisms of platelet membrane glycoproteins, genetic mutations of TBXA2R, the platelet-activating factor acetylhydrolase, and coagulation factor XIII.
platelet activating factor: A factor which, like PROSTAGLANDINS and LEUKOTRIENES, is released from cell membranes. It is a potent cause of INFLAMMATION and an activator of several cell types of the immune system.
It is rapidly destroyed and its effect is local. Compare platelet activating factor ELISA Kits from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
Platelet-activating factor, otherwise called a PAF, PAF-acether or AGEPC (acetyl-glyceryl-ether-phosphorylcholine) is an intense phospholipid activator and arbiter of numerous leukocyte capacities, including platelet total and degranulation, aggravation, and hypersensitivity.
Platelet activating factor synonyms, Platelet activating factor pronunciation, Platelet activating factor translation, English dictionary definition of Platelet activating factor. A minute, nonnucleated, disklike cytoplasmic body found in the blood plasma of mammals that is derived from a megakaryocyte and functions to promote.
Medical definition of platelet-activating factor: phospholipid that is produced especially by mast cells and basophils, causes the aggregation of blood platelets and the release of blood-platelet substances (as histamine or serotonin), and is a mediator of inflammation (as in asthma) —abbreviation PAF.
Research output: Contribution to journal › Article. Abstract. It has been shown that production of platelet-activating factor (PAF, 1-O-alkylacetyl-sn-glycerophosphocholine) by endothelial cells (EC) stimulated with tumor necrosis factor (TNF)-α and interleukin (IL)-1α requires the synthesis of new proteins and is regulated by anti Cited by: The platelet-activating factor receptor is a G-protein coupled receptor which binds platelet-activating factor.
The PAF receptor shows structural characteristics of the rhodopsin (MIM ) gene family and binds platelet-activating factor (PAF). PAF is a phospholipid (alkylacetyl-sn-glycerophosphorylcholine) that has been implicated as a mediator in diverse Aliases: PTAFR, PAFR, platelet activating.
factors influencing platelet function: adhesion, release, and aggregation J. FRASER MUSTARD and MARIAN A. PACKHAM Pharmacological Reviews June 1, Cited by: Several groups of antagonists of platelet‐activating factor (PAF) are reviewed.
The characteristics of PAF binding sites on mammalian cell membranes are described together with the activities of non‐specific and synthetic PAF‐antagonists. The specificity of the ginkgolides to bind to PAF‐receptors is discussed and the effects of these natural products in a range of biological.
Platelet-activating factor antagonism in rabbit platelets by the derivative of ochotensimine isolated from corydalis ochotensis. Asia Pacific Journal of Pharmacology. ;7(2) Lin, C. ; Wu, Yang-Chang ; Lu, S. ; Huang, T. ; Teng, C. / Platelet-activating factor antagonism in rabbit platelets by the derivative of Author: Chien-Huang Lin, Y.
Wu, S. Lu, T. Huang, C. Teng. Platelet-activating factor (PAF) is a phospholipid with potent, diverse physiological actions, particularly as a mediator of inflammation.
The synthesis, transport, and degradation of PAF are tightly regulated, and the biochemical basis for many of these processes has been elucidated in recent years. Many of the actions of PAF can be mimicked by structurally related Cited by: Platelet-activating factor (PAF) is a potent phospholipid activator of g-protein coupled receptor.
It also acts as as a mediator of biological functions such as platelet aggregation and degranulation, inflammation, and anaphylaxis at very low concentrations. Platelet activating factor 1.
By:By: Dr. Subodh KumarDr. Subodh Kumar Senior Scientist,Senior Scientist, Division of Animal GeneticsDivision of Animal Genetics Indian Veterinary Research Institute, IzatnagarIndian Veterinary Research Institute, Izatnagar 2. Title: Platelet-Activating Factor (PAF): A Review of its Role in Asthma and Clinical Efficacy of PAF Antagonists in the Disease Therapy VOLUME: 2 ISSUE: 1 Author(s):Alicja Kasperska-Zajac, Zenon Brzoza and Barbara Rogala Affiliation:Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology, ul.
3-go MajaZabrzePoland. Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the gold-standard of pharmacology texts – completely updated to reflect the latest research and developmentsA Doody’s Core Title for !
Goodman & Gilman’s: The Pharmacological .Define platelet-activating factor antagonist. platelet-activating factor antagonist synonyms, platelet-activating factor antagonist pronunciation, platelet-activating factor antagonist translation, English dictionary definition of platelet-activating factor antagonist.
a person who opposes another, often in a hostile manner: The man was his.Svenska synonymer. Antiheparinfaktor. Engelska synonymer. Factor, Platelet Activating — Phosphorylcholine, Acetyl Glyceryl Ether — Platelet Aggregating Factor — Aggregating Factor, Platelet — Platelet Aggregation Enhancing Factor — AGEPC — Thrombocyte Aggregating Activity — 1-Alkylacetyl-sn-glycerophosphocholine — 1 Alkyl 2 acetyl sn .